FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:264-265 January 22, 1998 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Falk, R. H.

To the Editor: In the review of the systemic amyloidoses by Falk et al. (Sept. 25 issue),¹ the comments about the treatment of immunoglobulin-light-chain–related (AL) amyloidosis with high-dose chemotherapy and stem-cell infusion may be premature. We and others have investigated the use of high-dose chemotherapy for a related disorder, multiple myeloma.² Although the reported experience with high-dose chemotherapy for myeloma involves more than 1000 patients, reports on this treatment for AL amyloidosis (in full manuscript form, including all the papers cited in the review) involve fewer than 10 patients.

We are aware that the authors have accumulated further, unpublished experience . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.